Following the latest data revealing the promise of cell therapies for lupus, all eyes were on how to pave the way to develop the first curative treatments for autoimmune patients

The 2nd Cell Therapy for Autoimmune Disease Summit returned to Philadelphia bigger and better after it's 2023 explosive debut as the only meeting covering every aspect of bringing cell therapies to the autoimmune space. This was your unmissable opportunity to learn the A-Zs of accelerating your candidates to be the first in the market and finally bring the cure for an autoimmune indication.

We join 30+ trailblazers including Cartesian Therapeutics, Bristol Myers Squibb, the University of Pennsylvania, ImmPACT Bio and more as they unveiled their latest clinical updates, next-generation candidates, novel antigen targets, and translational biomarkers to turbocharge the development of cell therapies for autoimmune disease.

With a brand new 2 tracked agenda, we heard in-depth presentations across preclinical development versus clinical strategy to strategically gain the insight your team needed to boost your candidates among industry pioneers. This year was the biggest edition of this meeting yet as this community expands to grasp every opportunity available.